Global Phase 2b Clinical Data for CytRx Corporation’s Aldoxorubicin to be Featured at the Connective Tissue Oncology Society Annual Meeting
Published: Oct 23, 2013
CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that additional preliminary data from its Phase 2b clinical trial demonstrating aldoxorubicin’s potential advantage over doxorubicin in the treatment of soft tissue sarcoma (STS) will be presented at the 18th Annual Connective Tissue Oncology Society (CTOS) Meeting on Thursday, October 31 at 4:30 p.m. Eastern time at the Sheraton New York Times Square Hotel.
Help employers find you! Check out all the jobs and post your resume.